Banner - Specialty Specific Content- HemOnc

Tab - HemOnc

For your specific specialty, access information below about the patients you're seeing and how to test for, diagnose, and manage iron deficiency anemia (IDA).


#1 IV iron in oncology clinics by mg volume*

#1 IV iron in oncology clinics
by mg volume*

*Based on Symphony Health PHAST Non-retail Mg Administration Volume Data (May 2017-April 2018).

33% of patients with solid tumors were reported to have IDA in a 2011 review looking at iron deficiency anemia in cancer patients1

IDA is a relevant concern in oncology and a risk for cancer patients

IDA Prevalence Oncology Population Chart

Condition and patient type2

Iron deficiency and iron deficiency-associated anemia are common complications in cancer patients, and the prevalence of anemia in patients with cancer is remarkably high. In these patients, iron regulation and homeostasis often are distorted. This may result in insufficient iron supply to erythroblasts with clinical sequelae of iron deficiency such as weakness, fatigue, and impaired physical fitness and well-being as well as anemia.

In your practice, you are commonly seeing patients that are also being treated by a gastroenterologist and/or an OB/GYN. It’s important to ask what they are experiencing and hearing from other doctors to get a full picture of their health and treatment journey. To learn more about what these other doctors may be reviewing with these particular patients, visit the gastroenterologist section and the OB/GYN section of this site.

Diagnosing and managing IDA1

One of the most common laboratory tests used to diagnose IDA is of serum ferritin, which generally reflects the status of iron stores. Transferrin saturation (TSAT), the percentage of hypochromic red cells (%HYPO), and the hemoglobin (Hb) content of reticulocytes (CHr) reveal the availability of iron.

Since serum ferritin, an acute-phase protein, can be elevated due to inflammation and liver cell damage, normal or elevated ferritin levels do not necessarily indicate sufficient iron stores, particularly in cancer patients. Therefore other routine blood tests may include C-reactive protein (CRP) and alanine aminotransferase (ALT) to check for inflammation and assess liver function.

See the common laboratory markers used to monitor IDA.

Injectafer restores iron

Injectafer is a dextran-free IV iron indicated for adult IDA patients of various etiologies, and is the only IV iron that delivers up to 1500 mg of iron in just 2 administrations, separated by at least 7 days.

Benefits of Injectafer IV Iron Administration Benefits of Injectafer IV Iron Administration

For adult patients weighing less than 50 kg (110 lb), give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course of treatment.

When administered via IV infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not <2 mg of iron per mL and administer over at least 15 minutes. When administered as a slow IV push, give at the rate of approximately 100 mg (2 mL) per minute.

One potential limitation to the use of IV iron in cancer patients might be the interaction of iron with certain chemotherapies, in particular anthracyclines and platium-based therapies.1 Formal drug interaction studies have not been performed with Injectafer.

Injectafer is not indicated to treat the symptoms of IDA.

Gradient Bar links- Choosing Injectafer

Choosing Injectafer: VIDEO LIBRARY

Choosing Injectafer: VIDEO LIBRARY

References - Specialty Specific Content